SG166001A1 - Methods of generating and screening for proteases with altered specificity - Google Patents

Methods of generating and screening for proteases with altered specificity

Info

Publication number
SG166001A1
SG166001A1 SG200704897-8A SG2007048978A SG166001A1 SG 166001 A1 SG166001 A1 SG 166001A1 SG 2007048978 A SG2007048978 A SG 2007048978A SG 166001 A1 SG166001 A1 SG 166001A1
Authority
SG
Singapore
Prior art keywords
proteases
methods
generating
screening
altered specificity
Prior art date
Application number
SG200704897-8A
Other languages
English (en)
Inventor
Jack Nguyen
Chris Thanos
Sandra Waugh Ruggles
Charles S Craik
Original Assignee
Catalyst Biosciences Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc, Univ California filed Critical Catalyst Biosciences Inc
Publication of SG166001A1 publication Critical patent/SG166001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
SG200704897-8A 2002-10-02 2003-10-02 Methods of generating and screening for proteases with altered specificity SG166001A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41538802P 2002-10-02 2002-10-02

Publications (1)

Publication Number Publication Date
SG166001A1 true SG166001A1 (en) 2010-11-29

Family

ID=32069849

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200704897-8A SG166001A1 (en) 2002-10-02 2003-10-02 Methods of generating and screening for proteases with altered specificity
SG2009070467A SG188669A1 (en) 2002-10-02 2003-10-02 Method of generating and screening for proteases with altered specificity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2009070467A SG188669A1 (en) 2002-10-02 2003-10-02 Method of generating and screening for proteases with altered specificity

Country Status (13)

Country Link
US (2) US20040146938A1 (ja)
EP (3) EP2444809A3 (ja)
JP (3) JP5376747B2 (ja)
KR (3) KR20100109969A (ja)
CN (2) CN101124484A (ja)
AU (2) AU2003282724B2 (ja)
CA (1) CA2501295A1 (ja)
MX (1) MXPA05003493A (ja)
NO (1) NO20052096L (ja)
NZ (2) NZ590187A (ja)
SG (2) SG166001A1 (ja)
WO (1) WO2004031733A2 (ja)
ZA (1) ZA200502867B (ja)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590187A (en) * 2002-10-02 2012-07-27 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
CA2534629C (en) * 2003-08-06 2016-01-19 University Of Maryland Biotechnology Institute Engineered proteases for affinity purification and processing of fusion proteins
EP1735438A2 (en) * 2004-04-12 2006-12-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
JP2006117594A (ja) * 2004-10-22 2006-05-11 Shiseido Co Ltd 活性型カスパーゼ−１４特異的抗体及びその作成方法
PL1866328T3 (pl) 2005-03-22 2011-05-31 Rohto Pharma Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
KR20150033726A (ko) * 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
CA2764775C (en) 2009-06-26 2019-02-26 University Of Florida Research Foundation, Inc. Rapid bed-side measurement of neutrophil elastase activity in biological fluids
US20120270241A1 (en) * 2009-09-23 2012-10-25 Bryan Philip N Systems and methods for evolving enzymes with desired activities
WO2012038049A2 (en) * 2010-09-22 2012-03-29 Roche Diagnostics Gmbh Amplification of distant nucleic acid targets using engineered primers
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP5851092B2 (ja) * 2010-12-24 2016-02-03 株式会社明治 ペプチド組成物、およびその製造方法
EP2658971A1 (en) 2010-12-28 2013-11-06 XOMA Technology Ltd. Cell surface display using pdz domains
CA2849669A1 (en) * 2011-09-23 2013-03-28 Pharmedartis Gmbh Novel serine protease variants
EP3929288A1 (en) * 2012-05-25 2021-12-29 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
IN2015DN01404A (ja) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
EP3456734B1 (en) * 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
KR102344861B1 (ko) 2014-02-26 2021-12-29 시에이치알. 한센 에이/에스 개선된 응유 특성을 갖는 키모신 변이체
US11512335B2 (en) * 2014-04-29 2022-11-29 Novartis Ag Vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3970748B1 (en) 2014-12-24 2024-07-24 NexImmune, Inc. Nanoparticle compositions and methods for immunotherapy
AU2016282825B2 (en) 2015-06-22 2022-11-17 Chr. Hansen A/S Variants of chymosin with improved properties
AR105867A1 (es) 2015-08-31 2017-11-15 Chr Hansen As VARIANTES DE QUIMOSINA CON PROPIEDADES MEJORADAS DE a-S1-CASEÍNA
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
BR112018010052A2 (pt) 2015-11-19 2019-02-05 Asclepix Therapeutics Llc peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
WO2017134301A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
US12019066B2 (en) * 2016-05-16 2024-06-25 Biomadison, Inc. Assay with synaptobrevin based moiety
CA3228729A1 (en) 2016-05-19 2017-11-23 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
EP3457860A1 (en) 2016-05-19 2019-03-27 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
MX2019003895A (es) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
BR102017010169A2 (pt) * 2017-05-15 2019-02-26 Remer Consultores Assessoria Empresarial Ltda. composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
GB201622422D0 (en) * 2016-12-30 2017-02-15 Dublin Inst Of Tech Peptide prediction
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
KR102675270B1 (ko) 2017-06-22 2024-06-17 버텍스 파마슈티칼스 인코포레이티드 변형된 막 유형 세린 프로테아제 １(ｍｔｓｐ－１) 폴리펩티드 및 사용 방법
EP3661536A4 (en) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
CN108241054B (zh) * 2017-12-26 2021-03-12 天津市中西医结合医院（天津市南开医院） 检测g蛋白偶联受体18的试剂在制备败血症诊断及病程监测和预后判断试剂中表达的应用
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
AU2019413431A1 (en) 2018-12-28 2021-07-08 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3129834A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020210455A1 (en) * 2019-04-09 2020-10-15 University Of Houston System Engineered chymotrypsins and uses thereof
CN110079514A (zh) * 2019-04-12 2019-08-02 江苏大学 一种制备蛋白酶3重组蛋白的方法
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
CN112322722B (zh) * 2020-11-13 2021-11-12 上海宝藤生物医药科技股份有限公司 检测16p11.2微缺失的引物探针组合物、试剂盒及其应用
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
US12049502B2 (en) 2022-11-30 2024-07-30 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763257A (en) * 1984-05-29 1998-06-09 Genencor International, Inc. Modified subtilisins having amino acid alterations
US5185258A (en) * 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6271012B1 (en) * 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5766842A (en) * 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst
US6165794A (en) * 1994-11-10 2000-12-26 The Regents Of The University Of California Suppression of proteolytic activity by dysfunctional protease formation
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
DE19743683A1 (de) * 1997-10-02 1999-04-08 Basf Ag Verfahren zur Änderung der Substratspezifität von Enzymen
US20030186329A1 (en) * 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
US20020068320A1 (en) * 2000-03-14 2002-06-06 Yanggu Shi Serine protease polynucleotides, polypeptides, and antibodies
DE19943177C2 (de) * 1999-09-09 2002-10-24 Dieter Jenne Verfahren zur Herstellung von aktiven Serienproteasen und inaktiven Varianten
US7030231B1 (en) * 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US20030171252A9 (en) * 2000-01-31 2003-09-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6630138B2 (en) * 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
US20020031801A1 (en) * 2000-03-24 2002-03-14 Millennium Pharmaceuticals, Inc. 18806, a novel trypsin serine protease-like molecule and uses thereof
WO2001094332A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
US7157596B2 (en) * 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
US20030104591A1 (en) * 2000-12-14 2003-06-05 Murray Christopher J. Methods and compositions for grafting functional loops into a protein
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
WO2003089648A1 (en) * 2002-04-22 2003-10-30 Novozymes Biotech, Inc. Methods for preparing variants of a dna sequence in filamentous fungi
US20040072276A1 (en) * 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
JP2005537032A (ja) * 2002-08-27 2005-12-08 コンパウンド セラピューティクス インコーポレーティッド アドザイムおよびその用途
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
NZ590187A (en) * 2002-10-02 2012-07-27 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
ES2373658T3 (es) * 2003-06-18 2012-02-07 Bayer Pharma Aktiengesellschaft Nuevas entidades biológicas y el uso de las mismas.
US20050002897A1 (en) * 2003-06-18 2005-01-06 Ulrich Haupts Biological entities and the pharmaceutical or diagnostic use thereof
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
JP5629423B2 (ja) * 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
US7974395B2 (en) * 2005-09-28 2011-07-05 Avaya Inc. Detection of telephone number spoofing
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP1976861A2 (en) * 2005-11-29 2008-10-08 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
KR20150033726A (ko) * 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) * 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEFINITION AND REDESIGN OF THE EXTENDED SUBSTRATE SPECIFICITY OF GRANZYME B *
IMPROVED BIOCATALYSTS BY DIRECTED EVOLUTION AND RATIONAL PROTEIN DESIGN *

Also Published As

Publication number Publication date
CN104630192A (zh) 2015-05-20
US20040146938A1 (en) 2004-07-29
ZA200502867B (en) 2007-09-26
AU2010201204B2 (en) 2012-09-20
JP2012254988A (ja) 2012-12-27
MXPA05003493A (es) 2005-09-30
EP2444810A2 (en) 2012-04-25
NZ590187A (en) 2012-07-27
WO2004031733A2 (en) 2004-04-15
EP2444809A2 (en) 2012-04-25
JP5376747B2 (ja) 2013-12-25
KR101132555B1 (ko) 2012-04-02
AU2003282724B2 (en) 2010-03-04
SG188669A1 (en) 2013-04-30
EP2444810A3 (en) 2013-01-02
US20090136477A1 (en) 2009-05-28
NO20052096D0 (no) 2005-04-29
EP1608947A2 (en) 2005-12-28
WO2004031733A3 (en) 2007-03-15
KR20120088836A (ko) 2012-08-08
AU2003282724A1 (en) 2004-04-23
CA2501295A1 (en) 2004-04-15
EP1608947A4 (en) 2009-06-17
NO20052096L (no) 2005-06-28
AU2010201204A1 (en) 2010-04-15
NZ539242A (en) 2009-07-31
JP2006518983A (ja) 2006-08-24
KR20050083717A (ko) 2005-08-26
CN101124484A (zh) 2008-02-13
EP2444809A3 (en) 2013-07-24
KR20100109969A (ko) 2010-10-11
JP2010099082A (ja) 2010-05-06

Similar Documents

Publication Publication Date Title
SG166001A1 (en) Methods of generating and screening for proteases with altered specificity
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
TW200745552A (en) HU-ASP 1 protease substrate and uses thereof
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
WO2005100556A3 (en) Cleavage of vegf and vegf receptor by wild-type and mutant proteases
DE10345772A1 (de) Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
HK1016495A1 (en) Phosphorous-containing cysteine and serine protease inhibitors
EP0975353A4 (en) PEPTIDYL-2-AMINO-1HYDROXYALKANESULPHONIC ACIDS AS CYSTEIN PROTEASE INHIBITORS
WO1996024650A3 (en) Cytoplasmic antiproteinase-2 and cytoplasmic antiproteinase-3 and coding sequences
WO2003095475A3 (en) Peptide compounds and their use as protease substrates
SG158739A1 (en) Aggrecanase molecules
DE69825733D1 (de) Spezifische inhibitoren der pankreatischen lipase und deren anwendungen
WO2002014264A3 (en) (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
Murayama et al. The unusual high molecular mass of Bothrops protease A, a trypsin-like serine peptidase from the venom of Bothrops jararaca, is due to its high carbohydrate content
AU2003247599A1 (en) Methods of modulating cytokinin related processes in a plant using b3 domain proteins
EP1385993B8 (en) Method of detecting and treating tuberous sclerosis complex associated disorders
ATE334174T1 (de) System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen
DE50105206D1 (de) Verfahren zum selektieren von inhibitoren für enzyme
DE60334316D1 (de) Frpb proteinmutante und verfahren zur erneuten faltung
DE60331414D1 (de) Aggrecanase-1- und -2-peptidsubstrate und verfahren
WO2002100333A3 (en) Inhibitors of reggamma
WO2003064597A3 (en) Aggrecanase molecules
WO2002081665A3 (en) Implantation serine proteinases
WO2003106385A3 (en) METHOD FOR SCREENING FUNGITOXIC COMPOUNDS
NZ525368A (en) Novel aggrecanase molecules